Be great to ask about time frames for heritage approvals for targets 2 and 3. Another big hit in one of those areas would really put a rocket under the share. Time for questions afterwards.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
